Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Employees - 92, CEO - Scott Plesha, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -2.04, Piotroski Score(max is 10): 4, Working Capital: $31397000, Total Assets: $137356000, Retained Earnings: $-113284000, EBIT: -67837000, Total Liabilities: $138857000, Revenue: $43304000

- Current Price $ - Analyst Target Price $